About Ono Pharmaceutical
Ono Pharmaceutical is a publicly listed company based in Osaka (Japan) founded in 1717. Pharmaceutical products are developed and manufactured for therapeutic areas. The company has 4,290 employees. Its chief executive, as recorded, is Akira Sagara. Ono Pharmaceutical offers products and services including Opdivo and Yervoy. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified. Its legal entity is Ono Pharmaceutical Co., Ltd.
Company details
Ono Pharmaceutical was founded in 1717 in Osaka, Japan, and operates within the pharmaceutical sector. Research and development efforts are focused on innovative medicines across various therapeutic areas. A range of products is manufactured and distributed, supported by licensing agreements and external collaborations to broaden the pipeline. Medical research is backed, and information is supplied to healthcare professionals and patients through established channels.
- Annual Revenue$3.1 B (USD)-3.14as on Mar 31, 2024
- Net Profit$318.89 M (USD)-60.89as on Mar 31, 2024
- EBITDA$575.22 M (USD)-50.32as on Mar 31, 2024
- Employee Count4,290
Products & Services of Ono Pharmaceutical
Ono Pharmaceutical offers a comprehensive portfolio of products and services, including Opdivo and Yervoy.
This product is utilized for cancer treatment, with approvals noted for various indications
This product is employed in combination therapies for cancer, as seen in press releases regarding liver cell cancer
Apps and channels of Ono Pharmaceutical
its YouTube channel 小野薬品 ONO PHARMACEUTICAL official has 489 subscribers and 19 videos.
Videos from Ono Pharmaceutical
The most watched videos on Ono Pharmaceutical's YouTube channel, 小野薬品 ONO PHARMACEUTICAL official (489 subscribers). Click a video to play it here.
More on 小野薬品 ONO PHARMACEUTICAL official .
People of Ono Pharmaceutical
19 people are tracked at Ono Pharmaceutical (15 in leadership, 4 in team); the tracked headcount is 4,290.
| Name | Role | Group |
|---|---|---|
Akira Sagara | CEO & President | Leadership |
Kunihiro Nakano | Senior Director, Asian Business Department | Leadership |
Yasunori Ninomiya | Head Of Global Marketing | Leadership |
Gyo Sagara | President and CEO | Leadership |
U. Shivraj Sohur | Vice President | Neurology Clinical Development | Leadership |
Masao Akamatsu | Associate Director, Business Development, Corporate Development & Strategy | Leadership |
Shigetaka Komeda | Head, Sales Field Digital Enablement, Sales Management | Leadership |
Takaaki Nakamura | Director, Primary Clinical Development Planning III (immunology & Speciality Area) | Leadership |
Tomoya Ohno | Senior Director Of Primary Clinical Development | Leadership |
Koichiro Terai | Head Of Business Development Japan HQ | Leadership |
Junsaku Kitagawa | Associate Director Of Clinical Pharmacology | Leadership |
Akifumi Fujii | Project Lead/director | Leadership |
Yukinori Nakata | Associate Director Of Global Market Access | Leadership |
Kunihiko Ito | Corporate Officer / Head Of Global Business | Leadership |
Kasumi Komiya | Senior Director Of Operations | Leadership |
Tomohiro H. | Corporate Communications | Team |
Mototsugu Tsutsui | Senior Manager | Team |
Masakazu Konno | Senior Manager | Team |
Junichi Yoshioka | Business Development Manager | Team |
Complete people profiles for Ono Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ono Pharmaceutical
Ono Pharmaceutical is a publicly listed company on the TSE with ticker symbol 4528 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Jun 1963
- Listed onTSE: 4528
- Listed entityONO Pharmaceutical Co., Ltd.
- Exchange sectorHealth technology
Web traffic of Ono Pharmaceutical
Websites that share an audience with Ono Pharmaceutical (ono.co.jp).
- Global rank#13,675,203
among all websites
- Category rank#8,475
Health · Biotechnology and Pharmaceuticals
- Bounce rate52%
- Pages per visit1.1
- DevicesDesktop 22% Β· Mobile 78%
Websites whose visitors overlap most with Ono Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
opdivo.jp | opdivo.jp | 100% | #3,078,803 | β | |
| kyowayakuhin.co.jp | 97% | 20.6K | #1,143,369 | View details | |
| toayakuhin.co.jp | 94% | 7.3K | #3,737,756 | View details | |
astrazeneca.co.jp | astrazeneca.co.jp | 92% | #587,112 | β | |
orencia.jp | orencia.jp | 92% | #5,168,109 | β | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 10 similar websites and full traffic analytics for Ono Pharmaceutical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ono Pharmaceutical
Complete news archive for Ono Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ono Pharmaceutical
Ono Pharmaceutical was founded in 1717.
Ono Pharmaceutical is headquartered in Osaka, Japan. It is registered at Osaka, Osaka Prefecture, Japan.
Akira Sagara is the CEO of Ono Pharmaceutical, as recorded in our data.
Ono Pharmaceutical has 4,290 employees.
Annual revenue of Ono Pharmaceutical is $3.1B as on Mar 31, 2024.
Ono Pharmaceutical was founded in 1717 in Osaka, Japan, and operates within the pharmaceutical sector. Research and development efforts are focused on innovative medicines across various therapeutic areas. A range of products is manufactured and distributed, supported by licensing agreements and external collaborations to broaden the pipeline. Medical research is backed, and information is supplied to healthcare professionals and patients through established channels.
Ono Pharmaceutical offers Opdivo and Yervoy.
Yes, Ono Pharmaceutical is publicly traded on TSE under the ticker symbol 4528.
Ono Pharmaceutical operates through Ono Pharmaceutical Co., Ltd.